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Abstract
In this study, we aimed to increase the sensitivity of human K562 and Meg-01 chronic myeloid leukemia (CML) cells to
nilotinib by targeting bioactive sphingolipids, in addition to investigating the roles of ceramide metabolizing genes in nilotinib
induced apoptosis. Cytotoxic effects of nilotinib, C8:ceramide, glucosyle ceramide synthase (GCS) and sphingosine kinase-1
(SK-1) inhibitors were determined by XTT cell proliferation assay and synergism between the agents was determined by
isobologram analysis. Also, quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) results demonstrated that
expression levels of longevity assurance (LASS) genes in response to nilotinib were correlated with sensitivity to nilotinib. For
the first time, The results of this study showed for the first time that nilotinib induces apoptosis through upregulating
ceramide synthase genes and downregulating SK-1 in CML cells in addition to inhibition of BCR/ABL. On the other hand,
manipulating bioactive sphingolipids toward generation/accumulation of ceramides increased the apoptotic effects of
nilotinib in CML cells.
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Introduction
Chronic myeloid leukemia (CML) is a disease of
hematopoietic stem cells, arising from a reciprocal
translocation between the long arms of chromosomes
9 and 22, known as the Philadelphia chromosome
[1]. This translocation causes a juxtaposition of ABL
and BCR genes, resulting in a BCR–ABL fusion
gene that encodes for BCR–ABL oncoprotein which
has constitutive tyrosine kinase activity and cytoplas-
mic relocalization [2]. Therefore, BCR–ABL can
activate numerous signal transduction pathways that
promote cell proliferation and survival [3–5], includ-
ing the RAS–ERK cascade, JAK–STAT, phosphati-
dylinositol 3-kinase (PI3K), and c-Myc pathways [6].
CML starts with a relatively slowly progressing
chronic phase, characterized by well-differentiated
leukemic cells in the blood. If not treated, the disease
can eventually progress into the blastic phase, often
via the accelerated phase [7]. Imatinib was the first
tyrosine kinase inhibitor used to specifically recog-
nize the adenosine triphosphate (ATP) binding site
of the BCR–ABL protein. However, its continuous
administration was associated with the development
of resistance, especially in the advanced phase or
blast crisis [8]. Different mechanisms were suggested
for imatinib resistance [9,10] such as mutations in
the ATP binding site of BCR–ABL [11], decreased
availability of the drug either by binding to plasma
proteins or by overexpression of transporter proteins
such as P-glycoprotein on the plasma membrane
[12], or overexpression of BCR–ABL. Furthermore,
also BCR–ABL independent resistance mechanisms
were suggested, such as aberrations in ceramide
generating and clearance genes [9]. Nilotinib, an
analog of imatinib, has higher selectivity to BCR–
ABL as compared to imatinib. Nilotinib disrupts the
ATP binding pocket of BCR–ABL tyrosine kinase
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and inhibits enzymatic activity by binding to the
inactive conformation of the protein and by blocking
its interaction with target proteins [13]. Nilotinib can
be used both alone [14] and in combination with
other agents for the treatment of CML. Nilotinib was
designed so that 32/33 mutations in the ATP binding
site of the BCR–ABL protein do not decrease its
binding efficiency [15].
Sphingolipids are a family of membrane lipids
responsible for regulation of the fluidity and subdomain
structure of the lipid bilayers [16]. Their bioactive
form, ceramide, which is a pro-apoptotic lipid [17], is
involved in the regulation of various aspects of cancer
pathogenesis and therapy, including apoptosis, cell
proliferation, cell migration, senescence, and inflam-
mation [18–21]. Ceramides are generated de novo by
the LASS (longevity assurance) gene family or by the
hydrolysis of sphingomyelin in various cellular
compartments. They mediate antiproliferative path-
ways and also inhibit pro-survival mechanisms [18],
mainly by regulating specific protein targets involving
AKT, phospholipase D, protein kinase C (PKC), and
mitogen-activated protein kinases (MAPKs) [22].
Increased ceramide levels have been observed in
response to several cancer chemotherapeutic agents
and radiotherapy [23]. The present study indicated
that manipulating bioactive sphingolipids toward the
generation/accumulation of ceramides increased the
apoptotic effects of nilotinib in human K562 and
Meg-01 chronic myeloid leukemia cells. Moreover,
expression levels of LASS genes in response to
nilotinib were correlated with sensitivity to nilotinib.
The results of this study may open the way to more
effective treatment of CML.
Methods
Reagents
Nilotinib was a gift from Novartis (USA). A 10 mM
stock solution of nilotinib was prepared with dimethyl-
sulfoxide (DMSO) and stored at7208C. C8:ceramide,
the glucosylceramide synthase (GCS) inhibitor N-(2-
hydroxy-1-(4-morpholinylmethyl)-2-phenylethyl)-de-
canamide, hydrochloride (PDMP), and sphingosine
kinase-1 (SK-1) inhibitor were obtained from Cayman
Chemicals (USA) and dissolved in DMSO.
Cell lines and culture conditions
K562 and Meg-01 human CML cells were obtained
from the German Collection of Microorganisms and
Cell Cultures (DSMZ, Germany). They were cul-
tured in RPMI 1640 growth medium containing
10% fetal bovine serum and 1% penicillin–strepto-
mycin (Invitrogen, USA) at 378C in 5% CO2.
Assessment of cellular growth by XTT cell proliferation
assay
The IC50 (drug concentration that inhibits cell growth
by 50%) values of nilotinib and ceramide, and IC10
(drug concentration that inhibits cell growth by 10%)
values of SK-1 inhibitor and PDMP, were determined
by XTT (sodium 3,30-[1[(phenylamino)carbonyl]-3,4-
tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic
acid hydrate) cell proliferation assay as described
previously [24]. Briefly, 96-well plates were seeded
with 26104 cells/well containing 200mL of growth
medium in the absence or presence of increasing
concentrations of the chemicals. The cells were
incubated at 378C in 5% CO2. After 72 h, cell
suspensions were treated with 50 mL of XTT reagent
for 4 h. Then, the absorbances of the samples were
measured by enzyme linked immunosorbent assay
(ELISA) reader (Multiskan Spectrum; Thermo Elec-
tron Corporation, Vantaa, Finland) at a wavelength of
490 nm. In combination analyses, we combined
increasing concentrations of nilotinib with those
corresponding to the IC10 values of PDMP and SK-
1 inhibitor, since we have shown previously that the
IC10 values of these chemicals are enough to inhibit
enzyme activity and provide accumulation of cera-
mides in the cells. On the other hand, since
C8:ceramide by itself triggers induction of the genera-
tion of apoptotic ceramide, it can be accepted to act as
a pro-drug. Therefore, we combined a concentration
corresponding to the IC50 value of C8:ceramide with
increasing concentrations of nilotinib.
Isobologram analysis for median dose effect
The CalcuSyn for Windows computer program
(Biosoft, Cambridge, UK) was used for isobologram
analysis [25] of dasatinib with C8:ceramide, PDMP,
and SK-1 inhibitor should be replaced with analysis
[25] of nilotinib with C8:ceramide, PDMP, and SK-
1 inhibitor. In this analysis, experimental data points,
represented by dots located below, on, or above the
line, indicated synergism, additivity, and antagonism,
respectively. The combination index (CI) is a
measure of the combined effects of two drugs, using
a median effect method. A CI value 51 indicates a
synergistic effect (0.1–0.5 strong synergism; 50.1
very strong synergism); a CI value of 1 indicates an
additive effect; and a CI value 41 indicates an
antagonistic effect (3.3–10 strong antagonism, 410
very strong antagonism).
Measurement of caspase-3 enzyme activity
Caspase-3 enzyme activity of the cells was assessed
using the caspase-3 colorimetric assay kit (R&D
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Systems, MN, USA) according to the manufacturer’s
instructions. First, cells that had been induced to
apoptosis with chemical treatment were collected by
centrifugation at 1000 rpm for 10 min. Then, the
collected cells were lysed by the addition of 100 mL of
cold lysis buffer (16). After incubation of the cells
on ice for 10 min, they were centrifuged at 14 000
rpm for 1 min. Supernatants were taken into new
Eppendorf tubes and the reaction mixture was
prepared in 96-well plates, adding 20 mL of assay
buffer (56), 25 mL of sample, 50 mL of sterilized
water, and 5 mL of caspase-3 colorimetric substrate.
After 2 h of incubation at 378C in a CO2 incubator,
absorbance of the plate was read at a wavelength of
405 nm (Multiskan Spectrum; Thermo Electron
Corporation).
Detection of changes in mitochondrial membrane potential
JC-1 mitochondrial membrane potential (MMP)
(Cell Technology, CA, USA) was used to measure
the loss of MMP in K562 and Meg-01 cells. Initially,
the cells that had been induced to apoptosis were
collected by centrifugation at 1000 rpm for 10 min.
Supernatants were removed and 500 mL of JC-1
stock solution, prepared as 1% dye, was added to the
pellets. After the incubation of cells for 15 min at
378C in a CO2 incubator, they were centrifuged at
1000 rpm for 5 min. Then, 2 mL of assay buffer was
added to the pellets and they were again centrifuged
for 5 min at 1000 rpm. All pellets were resuspended
with 500 mL of assay buffer, and 150 mL of each
mixture was added to a 96-well plate in triplicate.
The aggregate red form, which remains within the
intact mitochondria, has absorption/emission max-
ima of 585/590 nm, and the green monomeric form,
which is released to the cytoplasm due to loss of the
MMP, has absorption/emission maxima of 510/527
nm. The plate was read at these wavelengths using a
fluorescence ELISA reader (Multiskan Spectrum,
Thermo Electron Corporation).
Total RNA isolation and quantitative reverse
transcriptase-polymerase chain reaction
The expression levels of ceramide generating and
clearance genes and b-actin, the internal positive
control, were quantified by SYBR Green based
quantitative polymerase chain reaction (qPCR)
technique. In total, 36 106 cells/2 mL/well were
treated with increasing concentrations of nilotinib
and incubated for 24, 48, and 72 h in 5% CO2. Total
RNA was extracted using a Nucleospin Total RNA
isolation kit (Macherey-Nagel, Easton, PA, USA) as
described by the manufacturer. The amount and
quality of RNA were measured by a NanoDrop
Photospectrometer (NanoDrop 1000; Thermo,
USA). Some 5 mg of total RNA was reverse
transcribed into cDNA using reverse transcriptase
enzyme (Fermentas, USA). The reaction mixture
was incubated on ice for 10 min. After incubation at
428C for 50 min, the reactions were kept at 958C for
5 min. The resulting total cDNA was then used to
determine expression levels of LASS1, LASS2,
LASS4, LASS5, LASS6, SK-1, and GCS by using
LightCyclerH FastStart DNA Master SYBR Green I
kit (Roche, Basel, Switzerland). Expression levels of
b-actin were measured, as the internal positive
control. Finally, the data were analyzed with REST
2008 software (Corbett Research, Sydney, Australia).
The primer sequences were as follows [24]: LASS5-
F (50-ATCTTCTTCGTGAGGCTG-30), LASS5-R
(50-ATGTCCCAGAACCAAGGT-30) LASS1-F
(50-CTATACATGGA CACCTGGCGCAA-30),
LASS1-R (5’ TCAGAAGC GCTTGTCCTTCAC
CA-30); LASS2-F (50-GCTG GAGATTCACAT-
30), LASS2-R (50-GAAGACGAT GAAGAT-30);
LASS4-F (50-TGCTGTCCAGTTTCAACGAG-
30), LASS4-R (50-GAGGAAGTGTTT CTCCAG
CG-30); LASS6-F (50-CCTCGAGGGAT GGAT
TACAAGGATGACGACGATAAGATGGC AGG
GATCTTAGCCTGG-30), LASS6-R (50-CGG AA
TTCCGTTAATCATCCATGGAGCAGGA-30); SK-
1-F (50-CCGACGAGGACTTTGTGCTAAT-30),
SK-1-R (50-GCCTGTCCCCCCAAAGCATAA C-
30); GCS-F (50-ATGACAGAAAAAGTAGG CT-30),
GCS-R (50-GGACACCCCTGAGTGGAA-30); and b-
actin-F (50-CAGAGCAAGAGAGGCATCC T-30), b-
actin-R (50-TTGAAGGTCTCAAACATGA T-30).
Results
Antiproliferative effects of nilotinib, C8:ceramide,
PDMP, and SK-1 inhibitor on K562 and Meg-01
human CML cells
We have previously determined the antiproliferative
effects of nilotinib (IC50 42 nM [26]), C8:ceramide
(IC50 60 mM), PDMP (IC10 20 mM), and SK-1
inhibitor (IC10 7 mM [27]) on K562 cells. In this
study it was shown that increasing concentrations of
nilotinib (0.01–100 nM) decreased proliferation of
Ph+ Meg-01 cells in a dose-dependent manner. As a
result, the IC50 value of nilotinib was determined as
2.2 nM for Meg-01 cells [Figure 1(A)], which shows
that nilotinib is much more effective on Meg-01 cells
as compared to K562 cells. Increasing intracellular
concentrations of ceramides, i.e. C8:ceramide,
PDMP, or SK-1 inhibitor, also inhibited cell
proliferation in a dose-dependent manner as com-
pared to untreated controls. The IC50 value of
C8:ceramide was calculated to be 70 mM for
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Meg-01 cells [Figure 1(B)]. Since our previous
studies demonstrated that the IC10 value of PDMP
was sufficient to inhibit GCS enzyme activity [24],
we calculated the IC10 value of PDMP in Meg-01
cells to be 50 mM [Figure 1(C)]. Finally, we
determined the IC10 value of SK-1 inhibitor to be 5
mM [Figure 1(D)]. The antiproliferative effects of
C8:ceramide, PDMP, and SK-1 inhibitor at similar
concentrations have also been confirmed in various
types of cancer by independent studies [28–32].
Combination treatment with nilotinib and C8:ceramide,
PDMP, or SK-1 inhibitor significantly decreases
proliferation of K562 and Meg-01 cells
Combination studies of nilotinib with these chemi-
cals were also carried out to determine whether
induction of generation or accumulation of cera-
mides increased the antiproliferative effects of
nilotinib on K562 and Meg-01 cells. Cell prolifera-
tion data showed that the inhibition of ceramide
clearance by PDMP and SK-1 inhibitor increased the
cytotoxic effect of nilotinib as compared to any agent
alone in both K562 [Figure 2(A)] and Meg-01 cells
[Figure 2(B)]. Interestingly, induction of ceramide
generation by the application of C8:ceramide re-
sulted in significant increases in the antiproliferative
effects of nilotinib in K562 cells as compared to
PDMP and SK-1 inhibitor co-administration [Figure
2(B)]. In addition to these results, the CI values of
nilotinib in combination with C8:ceramide, PDMP,
and SK-1 inhibitor were 0.000017, 0.01403, and
0.03471, respectively, in K562 cells [Figure 3(A)].
Combinations of nilotinib with C8:ceramide,
PDMP, and SK-1 inhibitor gave CI values of
0.00029, 0.01893, and 0.02374, respectively, in
Meg-01 cells [Figure 3(B)]. A CI value51 indicates
a synergistic effect (0.1–0.5 strong synergism; 50.1
very strong synergism). These results demonstrated
that increasing intracellular concentrations of cer-
amide via the addition of exogenous ceramide or
inhibition of GCS and SK-1 enzymes in nilotinib
applied to CML cells resulted in very strong
synergism.
Combinations of nilotinib with ceramide metabolism
targeting agents increase caspase-3 enzyme activity
significantly
While cell proliferation data provide acceptable but
approximate data on the effects of these combina-
tions, we conducted the same kinds of experiments in
order to investigate the apoptotic effects of nilotinib
and increasing concentrations of ceramides via
ceramide mimetics/inhibitors. The results demon-
strated that the application of 1 and 10 nM
nilotinib caused 1.16- and 1.24-fold increases in
caspase-3 enzyme activity, while 20 mM PDMP, 7
mM SK-1 inhibitor, and 60 mM C8:ceramide alone
increased caspase-3 enzyme activity 1.28-, 1.12-,
and 1.36-fold, respectively, as compared to un-
treated controls. More importantly, combinations
Figure 1. Antiproliferative effects of nilotinib (A), C8:ceramide (B), PDMP (C), and SK-1 inhibitor (D) on Meg-01 cells. The IC50 values of
nilotinib and C8:ceramide, and the IC10 values of PDMP and SK-1 inhibitor, were calculated from cell proliferation plots. Error bars
represent standard deviations.
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of the same concentrations of nilotinib with the
same concentrations of PDMP, SK-1 inhibitor, or
C8:ceramide increased caspase-3 enzyme activity
2.52- and 2.72-, 1.67- and 1.8-, or 1.8- and 2.51-
fold, respectively, compared to untreated controls
(Figure 4). When caspase-3 enzyme activity was
analyzed for Meg-01 cells we also showed strong
synergistic effects, and similarly with K562 cells.
There were increases in caspase-3 enzyme activity
in response to nilotinib, PDMP, SK-1 inhibitor,
and C8:ceramide (Figure 5). Since caspase-3
enzyme activity has a vitally important role in
apoptosis, even a slight increase will result in
significant cell death. Therefore, increases in the
combinations were enough to repress proliferation
and induce apoptosis as determined by isobolo-
gram analysis of XTT cell proliferation data.
Loss of mitochondrial membrane potential in K562 and
Meg-01 cells treated with nilotinib and C8:ceramide,
PDMP, or SK-1 inhibitor
In order to confirm the caspase-3 enzyme activity
results and examine the roles of mitochondria in
nilotinib-induced apoptosis, we also determined the
loss of mitochondrial membrane potential. The
results of detection of MMP would also give
important clues about the synergistic apoptotic
effects of nilotinib with ceramide-increasing agents.
The results showed that nilotinib, C8:ceramide,
PDMP, and SK-1 inhibitor induced a loss of
MMP. In agreement with cell proliferation and
caspase-3 data, we determined that nilotinib in
combination with these agents induced apoptosis
significantly through the loss of MMP, as compared
to any agent alone, in both K562 (Figure 6) and
Figure 2. Antiproliferative effects of nilotinib in combination with C8:ceramide, PDMP, and SK-1 inhibitor on K562 (A) and Meg-01 cells
(B). Cytotoxicity was determined by XTT cell proliferation assay in a 72 h culture. Error bars represent standard deviations.
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Meg-01 cells (Figure 7). On the other hand,
supporting the previous data, the results of MMP
analysis revealed that the combination of nilotinib
with C8:ceramide induced apoptosis much more as
compared to other combinatorial treatments.
Nilotinib induces de novo ceramide generation and
ceramide accumulation as determined by increase in
expression levels of LASS genes and decrease in expression
levels of SK-1 and GCS genes
We attempted to examine the roles of ceramide
metabolizing genes in nilotinib-induced apoptosis.
To this aim, both types of cells were exposed to
increasing concentrations of nilotinib (0.1, 1, 10 nM
for K562 and 0.01, 0.1, 1 nM for Meg-01), and
expression levels of LASS1, LASS2, LASS4, LASS5,
LASS6, GCS, SK-1, and b-actin, as internal positive
control, were examined by qRT-PCR. The results
revealed significant increases in expression levels of
ceramide-generating LASS genes in a dose- and
time-dependent manner in K562 cells (Figure 8).
The most significant increases were observed in
LASS1, LASS2, and LASS5 in K562 cells exposed
to nilotinib for 24 h [Figure 8(A)], 48 h [Figure
8(B)], and 72 h [Figure 8(C)] and LASS1, LASS2,
Figure 3. Isobologram analysis of combination of nilotinib with C8:ceramide, PDMP, and SK-1 inhibitor in K562 (A) and Meg-01 (B) cells.
Figure 4. Percent changes in caspase-3 enzyme activity in response to combinations of nilotinib with C8:ceramide, PDMP, and SK-1
inhibitor in K562 cells. Error bars represent standard deviations, and when not apparent they are smaller than graph line thickness.
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LASS5, and LASS6 in Meg-01 cells (Figure 9).
There was also down-regulation of SK-1 and GCS in
K562 cells in a time- and dose-dependent manner
(Figure 8). There were 68% and 38% decreases in
expression levels of GCS and SK-1 in 10 nM
nilotinib-treated K562 cells after 72 h [Figure
8(C)]. While we observed a significant decrease in
SK-1 gene expression, there was almost no change in
Figure 5. Percent changes in caspase-3 enzyme activity in response to combinations of nilotinib with PDMP and SK-1 inhibitor (A) and
C8:ceramide (B) in Meg-01 cells. Error bars represent standard deviations, and when not apparent they are smaller than graph line thickness.
Figure 6. Percent changes in cytoplasmic/mitochondrial JC-1 in K562 cells exposed to combinations of nilotinib with C8:ceramide, PDMP,
and SK-1 inhibitor. Error bars represent standard deviations, and when not apparent they are smaller than graph line thickness.
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the expression pattern of GCS in Meg-01 cells
exposed to nilotinib (Figure 9).
Discussion
This study revealed the cytotoxic and apoptotic
effects of nilotinib on K562 and Meg-01 cells,
especially at lower concentrations. The results also
demonstrated that targeting the bioactive sphingoli-
pid metabolism to increase intracellular ceramide
concentrations increased the apoptotic effects of
nilotinib significantly. Nilotinib was developed for
selective inhibition of several tyrosine kinases, such as
BCR–ABL, Kit, and PDGF-R (platelet-derived
growth factor receptor) expressed in malignant cells
[33]. Nilotinib demonstrated significant efficacy
among patients with Philadelphia chromosome-
positive (Phþ) acute lymphoblastic leukemia and
patients with CML in all phases. However, there was
not complete cure of these malignancies [34]. A drug
cocktail including another apoptotic molecule such
as ceramide could be a good way to obtain better
preclinical models in order to reduce side effects and
define effective combinations. Although nilotinib is
highly specific for Phþ cells, there is still a possibility
of evolving adverse effects [35,36]. This is why
providing successful treatment in the clinic without
using high-dose nilotinib is an important goal.
Combination treatment using ceramides and meta-
bolites at such low concentrations of nilotinib,
leading to inhibition of cellular growth and induction
of apoptosis, is thus promising for the treatment of
CML. The results of this study revealed that the
combination of nilotinib and altered ceramide
metabolism has already given hopeful results. Ma-
nipulating the generation and/or accumulation of the
proposed tumor-suppressor lipid, ceramide, could
disarm a key mechanism for tumor viability and
Figure 7. Percent changes in cytoplasmic/mitochondrial JC-1 in Meg-01 cells in response to combinations of nilotinib with SK-1 inhibitor
and C8:ceramide (A) and PDMP (B). Error bars represent standard deviations, and when not apparent they are smaller than graph line
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growth [18]. Beckham et al. have shown that
targeting sphingolipid metabolism in different types
of cancers has therapeutic potential [37]. A key
regulator of ceramide/sphingosine 1-phosphate (S1P)
balance is SK-1, an oncogenic enzyme that phos-
phorylates sphingosine (the catabolite of ceramide) to
form S1P. SK-1 not only reduces the levels of
apoptotic ceramide but also the generated metabo-
lite, S1P, has significant antiapoptotic potential [38].
Pharmacological or RNA interference (RNAi) in-
hibition of SK-1 is sufficient to elicit apoptosis even
in chemo- or radioresistant cancer cell lines, demon-
strating the crucial role of SK-1 in cell survival
[39,40]. Thus, SK-1 enzyme inhibition can be a
good choice to support the treatment of patients with
CML. In our study, nilotinib in combination with
SK-1 inhibitor in both cell lines confirmed these
assumptions because of significant apoptotic effects.
There was an increase of caspase-3 enzyme activity,
loss of mitochondrial membrane potential, and also a
decrease in cell proliferation in response to inhibition
of SK-1. These results suggest that inhibition of SK-
1 facilitates treatment of CML in combination with
nilotinib therapy. GCS is an enzyme that glucosylates
the sphingolipid and transforms apoptotic ceramide
into antiapoptotic glucosylceramide, promoting che-
moresistance in K562 cells [41]. Liu et al. reported
that GCS is an important gene for the development
of drug resistance in cancer cells [42]. PDMP, a
strong GCS inhibitor, overcomes drug resistance in
different cell lines including colon, ovary, and breast
cancers, and also sensitizes cancer cells to doxor-
ubicin, paclitaxel, and vincristine [43–45]. Although
previous studies have shown that several approaches
inhibiting GCS reverse drug resistance in cancer
cells, there is no study in the literature showing the
synergistic effects of nilotinib and PDMP leading to
apoptosis. Hence from this perspective, the present
results showed for the first time that nilotinib in
combination with PDMP inhibited cell proliferation
and induced apoptosis significantly. In different types
of cancer cells exposed to different stress conditions
including chemotherapy and radiotherapy, there was
up-regulation of ceramide generating genes and
down-regulation of ceramide clearance genes
[23,24,46]. In this study, we examined the expres-
sion levels of LASS1, LASS2, LASS4, LASS5,
LASS6, SK-1, and GCS genes in response to
nilotinib, and the results demonstrated that nilotinib
increased the expression levels of LASS genes in both
cell lines and decreased the expression levels of SK-1
in both cells and GCS in K562 cells. Taken together,
these results suggest that targeting bioactive sphin-
golipids alone induces apoptosis in CML cells, while
the combination with nilotinib resulted in significant
induction of apoptosis. The results of this study may
Figure 8. Percent changes in expression levels of ceramide
metabolizing genes in response to nilotinib in K562 cells for
24 h (A), 48 h (B), and 72 h (C). Expression level of b-actin was
determined as internal positive control.
Figure 9. Percent changes in expression levels of ceramide
metabolizing genes in response to nilotinib in Meg-01 cells for
72 h. Expression level of b-actin was determined as internal
positive control.
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open a novel way of increasing the effectiveness of
nilotinib in CML treatment in addition to the
possibility of its use in other types of cancers.
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